Annexon is spotlighting tanruprubart, its C1q-targeting therapy for Guillain-Barre syndrome, as it seeks to address major treatment gaps in the rare autoimmune

Annexon is spotlighting tanruprubart, its C1q-targeting therapy for Guillain-Barre syndrome, as it seeks to address major treatment gaps in the rare autoimmune disorder. The company has reported Phase 3 results, with more clinical and regulatory updates pending.